Literature DB >> 17998933

Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.

F Pittella Silva1, R Hamamoto, M Kunizaki, M Tsuge, Y Nakamura, Y Furukawa.   

Abstract

Histone methylation is involved in the regulation of gene expression and DNA replication through alteration of chromatin structure. We earlier showed that SMYD3, a histone H3-lysine 4-specific methyltransferase, is frequently upregulated in human colorectal, liver and breast cancer compared to their matched non-cancerous cells, and that its activity is associated with the growth of these tumors. In the present study, we found that human cancer cells express both the full-length and a cleaved form of SMYD3 protein. Amino acid sequence analysis uncovered that the cleaved form lacks the 34 amino acids in the N-terminal region of the full-length protein. Interestingly, the cleaved protein and mutant protein containing substitutions at glycines 15 and 17, two highly conserved amino acids in the N-terminal region, revealed a higher histone methyltransferase (HMTase) activity compared to the full-length protein. Furthermore, the N-terminal region is responsible for the association with heat shock protein 90alpha (HSP90alpha). These data indicate that the N-terminal region plays an important role for the regulation of its methyltransferase activity and suggest that a structural change of the protein through the cleavage of the region or interaction with HSP90alpha may be involved in the modulation. These findings may help for a better understanding of the mechanisms that modulate the HMTase activity of SMYD3, and contribute to the development of novel anticancer drugs targeting SMYD3 methyltransferase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998933     DOI: 10.1038/sj.onc.1210929

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Crystal structure of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site architecture.

Authors:  Nualpun Sirinupong; Joseph Brunzelle; Jun Ye; Ali Pirzada; Lindsey Nico; Zhe Yang
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

2.  Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.

Authors:  Weiqi Fu; Nan Liu; Qi Qiao; Mingzhu Wang; Jinrong Min; Bing Zhu; Rui-Ming Xu; Na Yang
Journal:  J Biol Chem       Date:  2016-02-29       Impact factor: 5.157

3.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

4.  Function of the MYND Domain and C-Terminal Region in Regulating the Subcellular Localization and Catalytic Activity of the SMYD Family Lysine Methyltransferase Set5.

Authors:  Deepika Jaiswal; Rashi Turniansky; James J Moresco; Sabeen Ikram; Ganesh Ramaprasad; Assefa Akinwole; Julie Wolf; John R Yates; Erin M Green
Journal:  Mol Cell Biol       Date:  2020-01-03       Impact factor: 4.272

5.  Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Authors:  Lorna H Mitchell; P Ann Boriack-Sjodin; Sherri Smith; Michael Thomenius; Nathalie Rioux; Michael Munchhof; James E Mills; Christine Klaus; Jennifer Totman; Thomas V Riera; Alejandra Raimondi; Suzanne L Jacques; Kip West; Megan Foley; Nigel J Waters; Kevin W Kuntz; Tim J Wigle; Margaret Porter Scott; Robert A Copeland; Jesse J Smith; Richard Chesworth
Journal:  ACS Med Chem Lett       Date:  2015-08-27       Impact factor: 4.345

6.  Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.

Authors:  Shinya Hayami; Masanori Yoshimatsu; Abhimanyu Veerakumarasivam; Motoko Unoki; Yukiko Iwai; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Hiroki Yamaue; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Mol Cancer       Date:  2010-03-13       Impact factor: 27.401

7.  Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.

Authors:  Krishna R Kalari; Scott J Hebbring; High Seng Chai; Liang Li; Jean-Pierre A Kocher; Liewei Wang; Richard M Weinshilboum
Journal:  BMC Genomics       Date:  2010-06-04       Impact factor: 3.969

Review 8.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

9.  Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.

Authors:  Wilson Oliveira-Santos; Doralina Amaral Rabello; Antônio Roberto Lucena-Araujo; Fábio Morato de Oliveira; Eduardo Magalhaes Rego; Fábio Pittella Silva; Felipe Saldanha-Araujo
Journal:  Tumour Biol       Date:  2016-01-20

Review 10.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host.

Authors:  Winston Timp; Andrew P Feinberg
Journal:  Nat Rev Cancer       Date:  2013-06-13       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.